Philadelphia, Pennsylvania--(Newsfile Corp. - October 18, 2024) - Have You Held Inari Medical Shares Continuously Since Before February 24, 2022? Learn More About Your Rights at No Cost to You. Visit https://grabarlaw.com/the-latest/inari-shareholder-investigation/.
Grabar Law Office is investigating potential securities fraud and fiduciary duty breaches at Inari Medical, Inc. (NASDAQ: NARI). If you have held Inari shares since prior to February 24, 2022, you may be able to seek:
- Corporate reforms to protect your investment.
- Reimbursement of funds expended in litigation back to the company.
- A court-approved incentive award-all at no cost to you.
Learn More at:
https://grabarlaw.com/the-latest/inari-shareholder-investigation/, or contact Joshua Grabar at jgrabar@grabarlaw.com or call267-507-6085 for a free consultation.
Why Is Inari Medical Under Investigation?
A recently filed securities fraud class action complaint alleges the following misconduct by Inari's officers and directors:
- Touted misleading "record revenue" claims, attributing growth to the strength of its core VTE business.
- Failed to disclose that significant business expenses were used to improperly compensate medical professionals for using Inari products.
- Concealed an investigation by the U.S. Department of Justice for violations of the Anti-Kickback Statute and Civil False Claims Act.
- Misled investors about business expenses to hide improper conduct and maintain inflated stock prices.
As alleged, Inari's stockholders and the company itself were harmed by artificially inflated stock prices and mismanaged business practices.
Take Action Today: Protect Your Investment
Learn more about your rights:
https://grabarlaw.com/the-latest/inari-shareholder-investigation/ or contact Joshua Grabar
Email:jgrabar@grabarlaw.com - Phone: 267-507-6085
#InariMedical #NARI $NARI #SecuritiesFraud #InvestorRights #ShareholderAlert #CorporateGovernance #FiduciaryDuty #ClassAction #GrabarLaw #LegalAction #StockMarket
Attorney Advertising Disclaimer
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227049
